摘要
目的观察重组人表皮生长因子(rhEGF)凝胶联合他克莫司软膏外用对激素依赖性皮炎(HDD)的临床疗效和安全性。方法选取2014年3月-2016年1月湖北省黄石市爱康医院皮肤科诊治的面部HDD患者108例,随机分为他克莫司软膏对照组和rhEGF凝胶联合他克莫司软膏治疗组,每组54例。对照组外敷他克莫司软膏,2次/d,治疗组在对照组基础上加用rhEGF凝胶,2次/d。连续治疗4周,比较两组临床疗效、复发率和不良反应。结果治疗前两组表皮含水量、表皮油脂含量和表皮经皮水分丢失(TEWL)值无显著差异;治疗后两组表皮含水量和表皮油脂含量显著升高(P<0.05、0.01),TEWL值显著减低(P<0.05、0.01),但治疗组对表皮含水量和表皮油脂含量的升高作用和对TEWL值的减低作用显著优于对照组(P<0.05)。治疗组有效率为90.7%,显著高于对照组的72.2%(P<0.05)。随访6个月,治疗组复发率为11.1%,显著低于对照组的26.0%(P<0.05)。治疗组不良反应发生率为3.7%,对照组的5.6%,两组比较无显著性差异。结论 rhEGF凝胶联合他克莫司软膏治疗面部HDD,临床疗效显著、使用安全。
Objective To detect the clinical efficacy of Recombinant Human Epidermal Growth Factor （rhEGF） Gel combined with tacrolimus on facial hormone dependent dermatitis （HDD） and security. Methods Totally 108 facial HDD patients from Huangshi Aikang Hospital in Hubei province were enrolled, randomly divided into two groups. The control group （n = 54） was treated with tacrolimus （twice daily）, the treatment group was treated with rhEGF Gel and tacrolimus （twice daily） for 4 weeks. The clinical efficacy, recurernce rate, and adverse reactions were compared. Results There was no significant difference of skin moisture content, skin oil content, and TEWL values between the two groups before treatment. The increasing of skin moisture and skin oil content and decreasing of TEWL values in observation group was better than that in control group after treatment （P 〈 0.05）. The clinical efficacy was 90.7% in observation group, which was better than that of 72.2% in control group （P 〈 0.05）. The recurrence rate in observation group was 11.1%, which was significantly lower than that of 26.0% in control group （P 〈 0.05）. The incidence of adverse reactions was 3.7% in the observation group and 5.6% in the control group. There was no significant difference of adverse reaction rates between the two groups. Conelusion rhEGF Gel combined with tacrolimus showed significantly clinical efficacy and safety in treatment of facial HDD.
出处
《药物评价研究》
CAS
2016年第6期1012-1015,共4页
Drug Evaluation Research
